SHROOM2: A Potential Drug Target and Biomarker (G357)

Target Name: SHROOM2

NCBI ID: G357

SHROOM2

SHROOM2: A Potential Drug Target and Biomarker

Shroom2, a protein encoded by the gene SMY/YFP, is a member of the Shroom family which includes several plant-specific proteins involved in photosynthesis. The SHROOM2 gene has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and plant diseases.

The SHROOM2 protein is a key component of the chloroplast, which is the organ responsible for photosynthesis in plants. Chloroplast proteins are involved in various stages of photosynthesis, including the light-dependent and light-independent ones. The light-dependent stage is the most well-studied and is characterized by the formation of the PSI (Plastidic System Interface) complex, which is responsible for capturing and using light energy to produce ATP and NADPH for the production of glucose. The light-independent stage is also known as the non-light-dependent (NLD) stage and is characterized by the production of cutoff light.

The SHROOM2 protein is involved in the formation of the PSI complex and has been shown to be a key regulator of the chloroplast. It plays a crucial role in the maintenance of the PSI structure and stability, as well as the regulation of the rate of light-dependent photosynthesis.

In addition to its role in photosynthesis, the SHROOM2 protein is also involved in various signaling pathways. It has been shown to play a role in the regulation of cell growth, differentiation, and apoptosis. Furthermore, SHROOM2 has also been shown to be involved in the regulation of protein synthesis and cell survival.

The potential drug target for SHROOM2 is based on its involvement in various diseases, including cancer, neurodegenerative diseases, and plant diseases. SHROOM2 has been shown to be involved in the regulation of cancer cell growth and has been used as a potential therapeutic target for cancer treatment.

In neurodegenerative diseases, SHROOM2 has been shown to be involved in the regulation of the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The SHROOM2 protein has also been shown to be involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin, which are involved in the treatment of neurodegenerative diseases.

In plant diseases, SHROOM2 has been shown to be involved in the regulation of plant stress responses, including the regulation of photosynthesis and the regulation of cell wall biosynthesis. The SHROOM2 protein has also been shown to be involved in the regulation of plant responses to environmental stressors, including the regulation of salinity and temperature stress.

In conclusion, SHROOM2 is a protein that plays a crucial role in various aspects of plant photosynthesis, including the regulation of the PSI complex and the regulation of cell growth, differentiation, and apoptosis. Its potential drug target status makes it an attractive target for the development of new therapeutic strategies for a variety of diseases, including cancer, neurodegenerative diseases, and plant diseases.

Protein Name: Shroom Family Member 2

Functions: May be involved in endothelial cell morphology changes during cell spreading. In the retinal pigment epithelium, may regulate the biogenesis of melanosomes and promote their association with the apical cell surface by inducing gamma-tubulin redistribution (By similarity)

The "SHROOM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHROOM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets